Consecutive Use of the 52 mg Levonorgestrel-releasing Intrauterine System: Variations in Bleeding Patterns

Abstract

Objective Changes in bleeding patterns could influence the decisions of healthcare professionals to change the levonorgestrel-releasing intrauterine system (LNG-IUS) before 7 years of use, the recommended period of extended use. We evaluated changes in the bleeding patterns of users of the 52 mg LNG-IUS at the end of use of the first (IUS-1) and during the second device (IUS-2) use.

Methods We performed an audit of the medical records of all women who used two consecutive LNG-IUSs at the Family Planning clinic. We evaluated the sociodemographic/gynecological variables, the length of use, and the bleeding patterns reported in the reference periods of 90 days before removal of the IUS-1 and at the last return in use of IUS-2. We used the McNemar test to compare bleeding patterns. Statistical significance was established at p < 0.05.

Results We evaluated 301 women aged (mean ± SD) 32 (±6.1) years, with lengths of use of 68.9 (±16.8) and 20.3 (±16.7) months for the IUS-1 and IUS-2, respectively. No pregnancies were reported. Bleeding patterns varied significantly among women who used the IUS-2 for ≥ 7 months to 6 years when compared the bleeding patterns reported in IUS-1 use. Eighty-nine out of 221 (40%) women maintained amenorrhea and infrequent bleeding; 66 (30%) evolved to bleeding patterns with light flow, and 66 (30%) maintained or evolved to heavy flow patterns (p = 0.012). No differences were observed among the 80 women with ≤ 6 months of use.

Conclusion Changes in bleeding patterns occur during the use of LNG-IUS and should not be decisive for the early replacement of the device.

Resumo

Objetivo Variações no padrão de sangramento podem afetar a decisão de troca do sistema intrauterino de levonorgestrel (SIU-LNG) antes do período de uso estendido recomendado de 7 anos. Nós avaliamos mudanças no padrão de sangramento de usuárias ao final do uso do primeiro SIU-LNG 52 mg (SIU-1) e durante o uso do segundo dispositivo (SIU-2).

Métodos Revisamos os prontuários de todas as mulheres que inseriram consecutivamente o SIU-LNG no ambulatório de Planejamento Familiar. Foram avaliadas as variáveis sociodemográficas/ginecológicas, o tempo de uso, e os padrões de sangramento relatados nos períodos de referência de 90 dias antes da remoção do SIU-1 e no último retorno em uso do SIU-2. Usamos o teste de McNemar para comparar os padrões de sangramento. A significância estatística foi estabelecida em p < 0,05.

Resultados Analisamos os dados de 301 mulheres com idade (média ± desvio padrão [DP]) de 32 (±6,1) anos e tempo de uso de 68,9 (±16,8) e 20,3 (±16,7) meses para o SIU-1 e SIU-2, respectivamente. Nenhuma gravidez foi relatada. Os padrões de sangramento variaram significativamente durante o uso do SIU-2 (≥ 7 meses a 6 anos) em relação ao padrão relatado no SIU-1. Oitenta e nove das 221 (40%) mulheres mantiveram amenorreia e sangramento infrequente; 66 (30%) evoluíram para padrões de sangramento com fluxo leve e 66 (30%) mantiveram ou evoluíram para padrões de fluxo intenso (p = 0,012). Não foram observadas diferenças entre as 80 mulheres que utilizavam o SIU-2 há ≤ 6 meses.

Conclusão Mudanças nos padrões de sangramento ocorrem durante o uso do LNG-IUS e não devem ser decisivas para a troca precoce do dispositivo.

Keywords

levonorgestrel intrauterine system - consecutive use - bleeding patterns

Palavras-chave

Sistema Intrauterino De Levonorgestrel - uso consecutivo - padrão de sangramento

• References

• 1 Hubacher D. The levonorgestrel intrauterine system: reasons to expand access to the public sector of Africa. Glob Health Sci Pract 2015; 3 (04) 532-537 . Doi: 10.9745/GHSP-D-15-00178
• 2 Bahamondes L, Valeria Bahamondes M, Shulman LP. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods. Hum Reprod Update 2015; 21 (05) 640-651 . Doi: 10.1093/humupd/dmv023
• 3 Backman T, Huhtala S, Luoto R, Tuominen J, Rauramo I, Koskenvuo M. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol 2002; 99 (04) 608-613 . Doi: 10.1016/s0029-7844(01)01764-1
• 4 Rönnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999; 78 (08) 716-721 . Doi: 10.1034/j.1600-0412.1999.780810.x
• 5 Ali M, Bahamondes L, Bent Landoulsi S. Extended effectiveness of the etonogestrel-releasing contraceptive implant and the 20 µg levonorgestrel-releasing intrauterine system for 2 years beyond U.S. Food and Drug Administration product labeling. Glob Health Sci Pract 2017; 5 (04) 534-539 . Doi: 10.9745/GHSP-D-17-00296
• 6 McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. Am J Obstet Gynecol 2017; 216 (06) 586.e1-586.e6 . Doi: 10.1016/j.ajog.2017.01.036
• 7 Bahamondes L, Fernandes A, Bahamondes MV, Juliato CT, Ali M, Monteiro I. Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: A chart review of 776 women in Brazil. Contraception 2018; 97 (03) 205-209 . Doi: 10.1016/j.contraception.2017.10.007
• 8 Xiao BL, Zhou LY, Zhang XL, Jia MC, Luukkainen T, Allonen H. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 1990; 41 (04) 353-362 . Doi: 10.1016/0010-7824(90)90035-t
• 9 Natavio MF, Taylor D, Lewis RA, Blumenthal P, Felix JC, Melamed A. , et al. Temporal changes in cervical mucus after insertion of the levonorgestrel-releasing intrauterine system. Contraception 2013; 87 (04) 426-431 . Doi: 10.1016/j.contraception.2012.09.034
• 10 Moraes LG, Marchi NM, Pitoli AC, Hidalgo MM, Silveira C, Modesto W, Bahamondes L. Assessment of the quality of cervical mucus among users of the levonorgestrel-releasing intrauterine system at different times of use. Eur J Contracept Reprod Health Care 2016; 21 (04) 318-322 . Doi: 10.1080/13625187.2016.1193139
• 11 Hidalgo MM, Hidalgo-Regina C, Bahamondes MV, Monteiro I, Petta CA, Bahamondes L. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. Contraception 2009; 80 (01) 84-89 . Doi: 10.1016/j.contraception.2009.01.004
• 12 Seeber B, Ziehr SC, Gschlieβer A, Moser C, Mattle V, Seger C. , et al. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception 2012; 86 (04) 345-349 . Doi: 10.1016/j.contraception.2012.01.015
• 13 Teal SB, Turok DK, Chen BA, Kimble T, Olariu AI, Creinin MD. Five-year contraceptive efficacy and safety of a levonorgestrel 52-mg intrauterine system. Obstet Gynecol 2019; 133 (01) 63-70 . Doi: 10.1097/AOG.0000000000003034
• 14 Apter D, Gemzell-Danielsson K, Hauck B, Rosen K, Zurth C. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertil Steril 2014; 101 (06) 1656-62.e1 , 4
• 15 Goldstuck ND. Clarification of the role of the Jaydess(Skyla) LNG- IUS 13.5mg and Kyleena LNG-IUS 19.5mg as intrauterine contraceptive systems. Expert Rev Med Devices 2017; 14 (08) 593-599 . Doi: 10.1080/17434440.2017.1350169
• 16 Gemzell-Danielsson K, Inki P, Boubli L, O'Flynn M, Kunz M, Heikinheimo O. Bleeding pattern and safety of consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS)--a multicentre prospective study. Hum Reprod 2010; 25 (02) 354-359 . Doi: 10.1093/humrep/dep426
• 17 Heikinheimo O, Inki P, Schmelter T, Gemzell-Danielsson K. Bleeding pattern and user satisfaction in second consecutive levonorgestrel-releasing intrauterine system users: results of a prospective 5-year study. Hum Reprod 2014; 29 (06) 1182-1188 . Doi: 10.1093/humrep/deu063
• 18 Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1986; 34 (03) 253-260 . Doi: 10.1016/0010-7824(86)90006-5
• 19 Rowe P, Farley T, Peregoudov A, Piaggio G, Boccard S, Landoulsi S. , et al; IUD Research Group of the UNDP/UNFPA/WHO/World Bank Special Programme of Research; Development and Research Training in Human Reproduction. Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A. Contraception 2016; 93 (06) 498-506 . Doi: 10.1016/j.contraception.2016.02.024